Blue Zone Wealth Advisors LLC Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Blue Zone Wealth Advisors LLC purchased a new stake in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) during the first quarter, Holdings Channel.com reports. The firm purchased 14,350 shares of the company’s stock, valued at approximately $118,000.

Other large investors have also made changes to their positions in the company. Baldwin Brothers LLC MA grew its position in Nuvectis Pharma by 22.0% during the fourth quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock valued at $1,185,000 after purchasing an additional 25,660 shares in the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in Nuvectis Pharma in the fourth quarter worth approximately $160,000. Finally, Strs Ohio grew its position in Nuvectis Pharma by 59.0% in the fourth quarter. Strs Ohio now owns 6,200 shares of the company’s stock worth $51,000 after acquiring an additional 2,300 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Nuvectis Pharma in a research report on Wednesday, May 8th.

Nuvectis Pharma Stock Up 1.0 %

NVCT stock traded up $0.06 during trading hours on Friday, hitting $6.33. The company’s stock had a trading volume of 922,871 shares, compared to its average volume of 79,482. The company has a market capitalization of $116.22 million, a PE ratio of -4.49 and a beta of 0.49. Nuvectis Pharma, Inc. has a 12 month low of $5.85 and a 12 month high of $16.58. The stock has a 50 day moving average price of $6.61 and a two-hundred day moving average price of $7.69.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.15. Sell-side analysts expect that Nuvectis Pharma, Inc. will post -1.29 earnings per share for the current year.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.